Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) saw unusually-high trading volume on Monday . Approximately 1,480 shares changed hands during mid-day trading, an increase of 9% from the previous session’s volume of 1,360 shares.The stock last traded at $63.19 and had previously closed at $66.84.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Finally, BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Six investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Zealand Pharma A/S currently has an average rating of “Strong Buy”.

Zealand Pharma A/S Stock Down 3.5%

The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of 4.57 and a beta of 0.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10. The stock has a fifty day moving average of $76.20 and a two-hundred day moving average of $68.95.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. The firm had revenue of $7.76 million for the quarter, compared to analyst estimates of $4.54 million. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%. Sell-side analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.